HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Development of Novel HER2-Targeted Therapies Could Help Reshape Treatment for HER2+ Breast Cancer

February 18th 2025

Kelly E. McCann, MD, PhD, discusses how novel ADCs and targeted therapies could improve treatment strategies in HER2-positive breast cancer.

Dr McCann on the Treatment Paradigm for HER2+ Breast Cancer With Brain Metastases

February 13th 2025

Kelly E. McCann, MD, PhD, discusses current and evolving treatment strategies for patients with HER2-positive breast cancer who develop brain metastases.

Neoadjuvant Atezolizumab/Trastuzumab/Pertuzumab Is Effective and Safe in HER2+ Early Breast Cancer

February 10th 2025

Neoadjuvant atezolizumab plus trastuzumab, pertuzumab, and abbreviated epirubicin generated pCRs in patients with early HER2-positive breast cancer.

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Dr Krop on Zanidatamab Plus Evorpacept in HER2+ Metastatic Breast Cancer

February 7th 2025

Ian Krop, MD, PhD, discusses zanidatamab in combination with evorpacept in HER2-positive and HER2-low metastatic breast cancer.

KN026 Plus Docetaxel Demonstrates Efficacy in HER2+ Metastatic Breast Cancer

February 7th 2025

KN026 plus docetaxel elicited durable responses and a manageable safety profile in patients with recurrent/metastatic HER2-positive breast cancer.

Eribulin Proves Noninferior to Taxane as Combination Partner With Trastuzumab and Pertuzumab in HER2+ Breast Cancer

February 6th 2025

Adding eribulin to trastuzumab/pertuzumab rather than taxane resulted in a numerically longer median time to QOL deterioration and similar efficacy outcomes in HER2+ breast cancer.

Insights From SABCS 2024 and Future Directions in Breast Cancer

February 6th 2025

Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.

Dr Werutsky on Assessing the Prognostic Value of HER2-Low in Early Breast Cancer

February 5th 2025

Gustavo Werutsky, MD, PhD, discusses an exploratory analysis assessing the prognostic value of HER2-low in early breast cancer management.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

February 3rd 2025

The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.

Dr Bardia on the FDA Approval of T-DXd for HER2-Low/-Ultralow Metastatic Breast Cancer

January 30th 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of T-DXd for patients with pretreated HER2-low and -ultralow metastatic breast cancer.

Translating Data With Oral SERDs to Practice: EMBER-3, SERENA-2, and Ongoing Trials

January 30th 2025

Dr. Gandhi and Dr. Clifton discuss incorporating imlunestrant plus abemaciclib into treatment sequencing for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (BC), considering factors such as ESR1 mutation status, prior CDK4/6 inhibitor (CDK4/6i) use, and visceral metastases, while also highlighting key trials of selective estrogen receptor degraders (SERDs), including SERENA-2 and OPERA-01.

Imlunestrant Clinical Data: Insights From the EMBER and EMBER-3 Trials

January 30th 2025

Dr. Clifton and Dr. Gandhi review the EMBER trial program, discussing study designs, key findings from phase 1b and EMBER-3 trials of imlunestrant-based combinations, and insights into efficacy, safety, and subgroup outcomes in estrogen receptor–positive/HER2-negative (ER+/HER2–) advanced breast cancer (ABC).

FDA Approves Trastuzumab Deruxtecan for Pretreated HER2-Low and -Ultralow Metastatic Breast Cancer

January 27th 2025

The FDA approved T-DXd for unresectable/metastatic HR+, HER2-low/-ultralow breast cancer that progressed on endocrine therapy in the metastatic setting.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Approved and Investigational SERDs in HR+/HER2– Breast Cancer

January 23rd 2025

Dr. Gandhi and Dr. Clifton discuss the evolving role of oral selective estrogen receptor degraders (SERDs) in the treatment paradigm for hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer, considering patient characteristics, clinical scenarios, and the landscape of approved and investigational agents, including elacestrant, imlunestrant, and camizestrant.

Endocrine Sensitivity and the Prognostic and Clinical Implications

January 23rd 2025

Dr. Gandhi and Dr. Clifton explore the prevalence and mechanisms of resistance to first-line endocrine therapy combined with CDK4/6 inhibitors in hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer.

SHR-A1811 Maintains Efficacy, Safety in Pretreated HER2-Expressing/-Mutated Breast Cancer, Other Solid Tumors

January 22nd 2025

An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.

Odzer on ERBB2 Copy Number Ratio as a Predictive Biomarker in HER2+ Breast Cancer

January 22nd 2025

Nicole Odzer discusses the utility of ERBB2 copy number ratio as a predictive biomarker in HER2+ breast cancer.

Dr Krop on the Efficacy and Tolerability of SHR-A1811 in Advanced HER2+ Breast Cancer

January 20th 2025

Ian Krop, MD, PhD, discusses SHR-A1811, a third-generation antibody-drug conjugate for HER2-positive breast cancer.